Honeywell International Inc vs Health Care Select Sector SPDR Fund — how do they compare? Honeywell International Inc trades at $229.58 (market cap $71.66B), while Health Care Select Sector SPDR Fund trades at $160.11. The key difference: Honeywell International Inc pays a 4.21% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Honeywell International Inc nearer its low. Which is the better fit depends on your goals.
| HON | XLV | |
|---|---|---|
Market Cap | $71.66B | — |
Sector | Industrials | — |
52-Week High | $248.04 | $164.48 |
52-Week Low | $188.14 | $129.01 |
Enterprise Value | $96.01B | — |
Dividend Yield | 4.21% | — |
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $229.86, up 2.15% with a bullish technical signal and strong analyst support. The company maintains solid profitability with 10.89% net margin and 26.41% ROE, though recent earnings show some pressure with Q2 2026 expectations at $1.80 EPS. Recent developments include a completed 2:1 reverse stock split and the acquisition of Johnson Matthey's Catalyst Technologies business for £1.325 billion, positioning the company for growth in automation and industrial technology.
HON presents a compelling investment case with 65% analyst buy ratings and a $368.55 consensus price target representing 60% upside. However, risks include declining profit margins (12.63% in 2025 vs 14.81% in 2024), increasing debt-to-asset ratio (46.65% in 2025), and near-term earnings uncertainty post-spinoffs. The stock's valuation at 18.07 P/E appears reasonable given its market leadership and strategic repositioning.
XLV trades at $159.25, down 1.14% with neutral technical signals overall. The healthcare ETF shows mixed momentum with bullish moving averages but neutral oscillators. Recent news highlights XLV's defensive characteristics amid market volatility, with State Street upgrading healthcare to positive for Q3 2026. The fund's diversified approach offers stability compared to more volatile biotech-focused alternatives.
XLV presents a defensive opportunity with lower costs and steady performance, though upside may be limited in the current cycle. Key risks include patent cliff concerns and sector rotation away from defensive plays if market sentiment improves. The ETF's broad healthcare exposure provides cushion against individual stock volatility while benefiting from pipeline innovations.
Trailing returns across standard periods
Latest headlines on both assets
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →